Valneva to provide 40,000 IXCHIQ doses in France starting early April

Valneva (VALN) SE announced earlier that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Reunion with its vaccine IXCHIQ. In agreement and with support from the local public health agency, the Agence Regionale de Sante La Reunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorite de Sante, to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ remains available for purchase in France. Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, “Chikungunya outbreaks spread rapidly, so it is crucial to vaccinate as many people as possible to help contain the virus. We have the capacity to supply more doses and will continue working closely with Agence Regionale de Sante La Reunion to manage this outbreak locally and prevent its spread to other regions through international travel.”